Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

25.59 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Deciphera Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
Via Benzinga
Deciphera Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Deciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of Patients
Via Benzinga
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Earns Price Target Bump With Encouraging ESMO Presentation
Via Benzinga
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
Via Benzinga
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals: Q3 Earnings Insights
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Earnings Outlook For Deciphera Pharmaceuticals
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Where Deciphera Pharmaceuticals Stands With Analysts
Over the past 3 months, 7 analysts have published their opinion on Deciphera Pharmaceuticals (NASDAQ:DCPH) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
McDonald's Price Target Cut By This Analyst, Plus Cowen Predicts $362 For Domino's Pizza
Citigroup cut McDonald's Corporation (NYSE: MCD) price target from $275 to $246. McDonald's shares rose 0.5% to $245.00 in pre-market trading. 
Via Benzinga
SVB Leerink Maintains Outperform Rating for Deciphera Pharmaceuticals: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) and raise its price target from $21.00 to $25.00. Shares of Deciphera Pharmaceuticals are trading up... 
Via Benzinga
This Analyst Slashes PT On Meta Platforms, Plus Mizuho Predicts $440 For Adobe
Mizuho cut the price target for Adobe Inc (NASDAQ: ADBE) from $480 to $440. Adobe shares fell 1.3% to $389.82 in pre-market trading. 
Via Benzinga
Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday
Atlantic Equities raised the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $83 to $87. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock.... 
Via Benzinga
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
4 Analysts Have This to Say About Deciphera Pharmaceuticals
Within the last quarter, Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
Upgrades 
Via Benzinga
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer
Via Benzinga
Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.